ATE454447T1 - Peptidagonisten für prostata-spezifisches antigen und ihre verwendung - Google Patents
Peptidagonisten für prostata-spezifisches antigen und ihre verwendungInfo
- Publication number
- ATE454447T1 ATE454447T1 AT02789873T AT02789873T ATE454447T1 AT E454447 T1 ATE454447 T1 AT E454447T1 AT 02789873 T AT02789873 T AT 02789873T AT 02789873 T AT02789873 T AT 02789873T AT E454447 T1 ATE454447 T1 AT E454447T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- psa
- nucleic acids
- prostate
- relates
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000000556 agonist Substances 0.000 title abstract 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title abstract 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- -1 host cells Proteins 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 abstract 1
- 239000002987 primer (paints) Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33457501P | 2001-11-30 | 2001-11-30 | |
| US33466901P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/037805 WO2003047506A2 (en) | 2001-11-30 | 2002-11-26 | Peptide agonists of prostate-specific antigen, and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454447T1 true ATE454447T1 (de) | 2010-01-15 |
Family
ID=26989272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02789873T ATE454447T1 (de) | 2001-11-30 | 2002-11-26 | Peptidagonisten für prostata-spezifisches antigen und ihre verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7247615B2 (https=) |
| EP (1) | EP1461073B1 (https=) |
| JP (1) | JP4364643B2 (https=) |
| AT (1) | ATE454447T1 (https=) |
| AU (1) | AU2002352913B2 (https=) |
| CA (1) | CA2468258C (https=) |
| DE (1) | DE60235041D1 (https=) |
| DK (1) | DK1461073T3 (https=) |
| ES (1) | ES2337454T3 (https=) |
| WO (1) | WO2003047506A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902121B2 (en) * | 2001-07-02 | 2011-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | MHC-antigen arrays for detection and characterization of immune responses |
| US20070196346A1 (en) * | 2003-08-21 | 2007-08-23 | Brown Michael P | Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer |
| WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
| WO2006122050A2 (en) | 2005-05-05 | 2006-11-16 | The Government Of The United States Of America, As Represented By The Secretary | Methods and compositions for detecting immune responses |
| DK1989224T3 (da) | 2006-02-24 | 2011-02-14 | Us Gov Health & Human Serv | Immunogene peptider og anvendelsesmetoder |
| US20080095790A1 (en) * | 2006-10-24 | 2008-04-24 | Perambakam Supriya M | Methods of Treating Prostate Cancer |
| CN100522460C (zh) * | 2007-12-15 | 2009-08-05 | 江西江铃底盘股份有限公司 | 一种桥壳总成的焊接夹具及焊接工艺 |
| JP2013504599A (ja) * | 2009-09-14 | 2013-02-07 | ベイラー リサーチ インスティテュート | ランゲルハンス細胞に向けられたワクチン |
| WO2012006634A2 (en) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| US8557777B2 (en) | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
| US20120263754A1 (en) | 2011-02-15 | 2012-10-18 | Immune Design Corp. | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| WO2013019445A2 (en) | 2011-07-29 | 2013-02-07 | Health Research, Inc. | Anti-angiogenic peptides and uses thereof |
| JP6312141B2 (ja) | 2012-03-30 | 2018-04-18 | 国立大学法人京都大学 | 前立腺がん検査用尿中バイオマーカー |
| KR102136433B1 (ko) | 2012-05-16 | 2020-07-22 | 이뮨 디자인 코포레이션 | Hsv-2 백신 |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| CA2939093A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| JP2017515841A (ja) | 2014-05-13 | 2017-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| EP3169352A1 (en) | 2014-07-15 | 2017-05-24 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| US20190183870A1 (en) | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| EP4706777A2 (en) | 2016-04-15 | 2026-03-11 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| IL262365B2 (en) | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| PT3596116T (pt) | 2017-03-16 | 2023-12-04 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras de pd-l1 variante e suas utilizações |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| MX2019011599A (es) | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
| KR102754876B1 (ko) | 2017-08-24 | 2025-01-13 | 버베리안 노딕 에이/에스 | 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법 |
| WO2019040994A1 (en) | 2017-09-01 | 2019-03-07 | The Australian National University | IMMUNOREGULATOR MOLECULES AND USES THEREOF |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SMT202600062T1 (it) | 2017-10-18 | 2026-03-09 | Alpine Immune Sciences Inc | Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| AU2019345151B2 (en) | 2018-09-19 | 2025-04-17 | Alpine Immune Sciences, Inc. | Methods and uses of variant CD80 fusion proteins and related constructs |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| MX2021005560A (es) | 2018-11-20 | 2021-06-23 | Bavarian Nordic As | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| EP4438054A3 (en) | 2019-04-17 | 2025-01-08 | Alpine Immune Sciences, Inc. | Methods and uses of variant icos ligand (icosl) fusion proteins |
| CN114867491B (zh) | 2019-11-20 | 2025-08-15 | 巴法里安诺迪克有限公司 | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| KR20240019124A (ko) | 2021-05-07 | 2024-02-14 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법 |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6946133B1 (en) * | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
| AU8259798A (en) * | 1997-06-20 | 1999-01-04 | George G Klee | Method for detection of breast cancer |
| ES2375948T3 (es) * | 2000-05-12 | 2012-03-07 | Northwest Biotherapeutics, Inc. | Procedimiento para aumentar la presentación de clase i de ant�?genos exógenos por células dendr�?ticas humanas. |
-
2002
- 2002-11-26 US US10/497,003 patent/US7247615B2/en not_active Expired - Lifetime
- 2002-11-26 WO PCT/US2002/037805 patent/WO2003047506A2/en not_active Ceased
- 2002-11-26 ES ES02789873T patent/ES2337454T3/es not_active Expired - Lifetime
- 2002-11-26 AU AU2002352913A patent/AU2002352913B2/en not_active Expired
- 2002-11-26 DE DE60235041T patent/DE60235041D1/de not_active Expired - Lifetime
- 2002-11-26 EP EP02789873A patent/EP1461073B1/en not_active Expired - Lifetime
- 2002-11-26 JP JP2003548767A patent/JP4364643B2/ja not_active Expired - Lifetime
- 2002-11-26 DK DK02789873.3T patent/DK1461073T3/da active
- 2002-11-26 CA CA2468258A patent/CA2468258C/en not_active Expired - Lifetime
- 2002-11-26 AT AT02789873T patent/ATE454447T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US20050054575A1 (en) | 2005-03-10 |
| AU2002352913A1 (en) | 2003-06-17 |
| EP1461073A4 (en) | 2007-01-17 |
| ES2337454T3 (es) | 2010-04-26 |
| DK1461073T3 (da) | 2010-03-29 |
| WO2003047506A2 (en) | 2003-06-12 |
| CA2468258A1 (en) | 2003-06-12 |
| DE60235041D1 (de) | 2010-02-25 |
| US7247615B2 (en) | 2007-07-24 |
| EP1461073A2 (en) | 2004-09-29 |
| WO2003047506A3 (en) | 2004-07-15 |
| EP1461073B1 (en) | 2010-01-06 |
| AU2002352913B2 (en) | 2008-05-29 |
| CA2468258C (en) | 2011-10-11 |
| JP2005511037A (ja) | 2005-04-28 |
| JP4364643B2 (ja) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE454447T1 (de) | Peptidagonisten für prostata-spezifisches antigen und ihre verwendung | |
| HUP0401591A2 (hu) | Új receptor-nukleinsavak és- polipeptidek | |
| WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
| MXPA04008077A (es) | Anticuerpos ant-a° y su uso. | |
| AU2014317884B2 (en) | Immune system modulators | |
| WO2001055206A8 (en) | Nucleic acids, proteins, and antibodies | |
| WO2001055317A3 (en) | Nucleic acids, proteins, and antibodies | |
| WO2003034903A3 (en) | Psma antibodies and protein multimers | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| WO2004024750A3 (en) | Cd44-binding ligands | |
| AU2020200990A1 (en) | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies | |
| AU2014317884A1 (en) | Immune system modulators | |
| MX2023006773A (es) | Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos. | |
| US20130296252A1 (en) | Muc18 targeting peptides | |
| MXPA05007940A (es) | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. | |
| WO2003068800A3 (en) | Isolated peptides which bind to hla molecules and uses thereof | |
| WO2016144650A1 (en) | Immune system modulators and compositions | |
| WO2003103474A3 (en) | DIAGNOSTIC MARKERS FOR NERVOUS SYSTEM DISORDERS | |
| EP1627916A4 (en) | ANTI-BAMBI ANTIBODIES AND THOSE CONTAINING DIAGNOSTIC OR REMEDIES FOR THICK-CANCER AND LIVER CANCER | |
| DK1399482T3 (da) | Bestemmelse af bone-sialoprotein i kropsvæsker til on-kologiske problemstillinger | |
| WO2004113361A3 (en) | Novel prokineticin receptor isoforms and methods of use | |
| AU2002336244A1 (en) | Trp2 isoform trp2-6b containing hla-a2-restricted epitopes | |
| TW200500465A (en) | Novel humanized anti-vap-1 monoclonal antibody | |
| WO2001055313A8 (en) | Nucleic acids, proteins, and antibodies | |
| ATE527354T1 (de) | Diabetogene epitope |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1461073 Country of ref document: EP |